Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Not yet recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 3Rhabdoid Tumor 1Recurrence 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 100Radiotherapy 49Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 22Bevacizumab 22Lomustine 16Nivolumab 14Surgical Procedures, Operative 10atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioblastoma × gallium maltolate × 1 year × Clear all
NCT07515924 2026-04-07

Oral Gallium Maltolate for Recurrent Glioblastoma

Medical College of Wisconsin

Phase EARLY_PHASE1 Not yet recruiting
8 enrolled
CNS

Glioblastoma

NCT06404034 2026-03-04

Expanded Access to Gallium Maltolate (GaM)

Imaging Biometrics, LLC

No longer available
CNS

Glioblastoma

NCT04319276 2025-11-03

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Medical College of Wisconsin

Phase 1 Active not recruiting
26 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡